All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

The use of estradiol metered-dose transdermal spray in clinical practice

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10387154" target="_blank" >RIV/00216208:11130/18:10387154 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064203:_____/18:10387154 RIV/75010330:_____/18:00012331

  • Result on the web

    <a href="https://doi.org/10.1080/13697137.2018.1504916" target="_blank" >https://doi.org/10.1080/13697137.2018.1504916</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1080/13697137.2018.1504916" target="_blank" >10.1080/13697137.2018.1504916</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    The use of estradiol metered-dose transdermal spray in clinical practice

  • Original language description

    Objective: The aim of this study was to evaluate the use of novel estradiol metered-dose transdermal spray (EMDTS) in the treatment of acute climacteric syndrome. Methods: A multicenter open-label trial was conducted with a 24-week intervention. EMDTS 1.53 mg was given to symptomatic menopausal women. The Menopause Rating Scale (MRS) was used to assess the climacteric syndrome severity. The Friedman non-parametric test and a post-hoc test with Bonferroni correction were used for statistical evaluation. Results: A total of 132 women were enrolled in 20 centers, of whom 123 (93.2%) completed the study. The average age of patients was 53.8 years (37-65 years). The study was discontinued by 6.8% of women. The patients were checked at the beginning of the study, and after 12 and 24 weeks. There was a statistically significant drop (p &lt; 0.001) in MRS values both after 12 and 24 weeks of therapy. The average MRS values improved by 66.2% between the first and the third visits. The most significant improvement was manifested in patients with initial moderate climacteric syndrome (70.9%). Conclusion: This study confirms that application of EMDTS offers a novel treatment option for climacteric symptoms.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30214 - Obstetrics and gynaecology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Climacteric

  • ISSN

    1369-7137

  • e-ISSN

  • Volume of the periodical

    21

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    5

  • Pages from-to

    549-553

  • UT code for WoS article

    000453060600007

  • EID of the result in the Scopus database

    2-s2.0-85054560339